(Q74462999)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10029609%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

title

Mesalamine in the treatment of mild to moderate active Crohn's ileitis: results of a randomized, multicenter trial (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10029609%20AND%20SRC:MED&resulttype=core&format=json

multicenter clinical trial

10 November 2019

main subject

1 reference

1 reference

C Prantera

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10029609%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

M Cottone

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10029609%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

F Pallone

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10029609%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

V Annese

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10029609%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

A Franzè

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10029609%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

R Cerutti

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10029609%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

G Bianchi Porro

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10029609%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

language of work or name

English

0 references

publication date

1 March 1999

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10029609%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10029609%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

volume

116

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10029609%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10029609%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

page(s)

521-526

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10029609%20AND%20SRC:MED&resulttype=core&format=json

Mesalamine capsules for the treatment of active Crohn's disease: results of a 16-week trial. Pentasa Crohn's Disease Study Group

10 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970172-1

A randomized, double-blind, placebo-controlled trial of the oral mesalamine (5-ASA) preparation, Asacol, in the treatment of symptomatic Crohn's colitis and ileocolitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970172-1

Oral 5-aminosalicylic acid (Asacol) in the maintenance treatment of Crohn's disease. The Italian IBD Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970172-1

Mesalamine in the maintenance treatment of Crohn's disease: a meta-analysis adjusted for confounding variables

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970172-1

5-Aminosalicylic acid in the treatment of Crohn's disease. A 16-week double-blind, placebo-controlled, multicentre study with Pentasa

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970172-1

Second trial of mesalamine therapy in the treatment of active Crohn's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970172-1

Long-term follow-up of patients with Crohn's disease. Relationship between the clinical pattern and prognosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970172-1

Effect of sulphapyridine, 5-aminosalicylic acid, and placebo in patients with idiopathic proctitis: a study to determine the active therapeutic moiety of sulphasalazine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970172-1

5-Aminosalicylic acid enema in the treatment of distal ulcerative colitis, proctosigmoiditis, and proctitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970172-1

5-Aminosalicylic Acid as Enemas or Suppositories in Distal Ulcerative Colitis?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970172-1

Concentrations of 5-ASA and Ac-5-ASA in human ileocolonic biopsy homogenates after oral 5-ASA preparations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970172-1

A comparison of budesonide and mesalamine for active Crohn's disease. International Budesonide-Mesalamine Study Group.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970172-1

Delivery and fate of oral mesalamine microgranules within the human small intestine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970172-1

A comparison of budesonide with prednisolone for active Crohn's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970172-1

10.1016/S0016-5085(99)70172-1

7 January 2021

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10029609%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

1 reference